Specifically, SBF2-AS1 is highly present in the exosomes secreted by TMZ-resistant GBM cells, suggesting that the detection of serum SBF2-AS1 holds hope for diagnosing therapy-resistant GBM [42]. The gene discussed is SBF2; the disease is glioblastoma.